Methotrexate Drug Interactions: Complete Clinical Guide with FDA Data

Methotrexate (MTX) is a cornerstone antimetabolite used across multiple therapeutic domains: rheumatoid arthritis, psoriasis, certain malignancies, and inflammatory bowel disease. Its mechanism as a dihydrofolate reductase (DHFR) inhibitor confers both therapeutic benefit and significant toxicity risk—particularly when combined with interacting medications. According to FDA drug labeling, methotrexate has multiple contraindicated and major interactions requiring vigilant clinical management. This guide synthesizes FDA-sourced interaction data to inform prescribing decisions and pharmacokinetic monitoring strategies.

What Methotrexate Is and Why Interactions Matter

Methotrexate acts as a competitive inhibitor of DHFR, disrupting folate-dependent one-carbon transfer reactions essential for nucleotide synthesis and cellular proliferation. This mechanism underlies both therapeutic efficacy and dose-limiting toxicity. Methotrexate is highly protein-bound (approximately 50%), undergoes variable hepatic metabolism, and depends on renal tubular secretion for elimination. These pharmacokinetic properties make MTX particularly vulnerable to drug-drug interactions that alter protein binding, hepatic clearance, or renal elimination—interactions that can rapidly escalate serum concentrations and trigger severe toxicity.

Contraindicated Combinations: Do Not Use Together

The FDA labels for methotrexate identify seven contraindicated drug combinations that mandate absolute avoidance:

NSAIDs and High-Dose Methotrexate

NSAIDs represent one of the most clinically relevant contraindicated interactions. According to FDA labeling, NSAIDs should not be administered prior to or concomitantly with high-dose methotrexate. The mechanism involves competitive inhibition of methotrexate's renal tubular secretion; NSAIDs reduce glomerular filtration and block active secretion in the proximal tubule, elevating and prolonging serum MTX concentrations. FDA-documented outcomes include deaths from severe hematologic and gastrointestinal toxicity. Clinically, this interaction poses the greatest risk when MTX doses exceed 30 mg/week or when high-dose parenteral MTX is used for malignancy. Patients must be counseled to avoid all NSAIDs, including over-the-counter formulations (ibuprofen, naproxen), throughout MTX therapy and for 48 hours post-infusion in high-dose regimens. Acetaminophen remains a safe alternative for analgesia; low-dose aspirin (81 mg daily) for cardiovascular indication is generally acceptable if renal function permits.

Trimethoprim-Sulfamethoxazole (TMP-SMX)

This antibiotic combination is contraindicated per FDA labeling due to dual mechanisms: sulfonamides displace methotrexate from plasma protein binding and compete with MTX for active renal secretion. Both effects increase unbound (free) methotrexate concentrations, elevating toxicity risk. Clinically, patients requiring antimicrobial prophylaxis or treatment while on methotrexate should use alternative agents (doxycycline, fluoroquinolones, or macrolides, depending on indication) with careful dose adjustment if renal impairment exists.

Nitrous Oxide

Nitrous oxide is contraindicated in methotrexate-treated patients. FDA labeling notes that this anesthetic potentiates MTX effects on folate-dependent metabolic pathways, increasing risk of severe adverse reactions. The mechanism reflects nitrous oxide's own DHFR inhibition, which compounds methotrexate's depletion of active folate cofactors. Regional anesthesia or alternative general anesthetics (propofol, isoflurane, sevoflurane) are preferred for MTX-treated patients requiring surgical procedures.

Natalizumab and Natalizumab-sztn

Both natalizumab formulations are contraindicated with methotrexate in Crohn's disease and other conditions due to compounded immunosuppression and increased risk of progressive multifocal leukoencephalopathy (PML) and serious infections. These biologic agents must not be combined with MTX. Sequential therapy or alternative monotherapy should be considered.

Acitretin

Acitretin (systemic retinoid) is contraindicated with methotrexate due to increased hepatotoxicity risk. Both agents are hepatotoxic; combined use elevates transaminases and fibrosis risk significantly. Patients requiring retinoid therapy should discontinue MTX or switch to alternative therapeutics.

Sepiapterin

Sepiapterin, a cofactor used in tetrahydrofolate metabolism disorders, is contraindicated with methotrexate. Because methotrexate inhibits DHFR and disrupts the conversion of sepiapterin to tetrahydrobiopterin (BH4), concurrent use impairs BH4 synthesis and therapeutic efficacy of sepiapterin.

Major Interactions: Require Dose Adjustment and Monitoring

NSAIDs (Non-High-Dose Regimens)

When low-dose methotrexate is used (e.g., 15–25 mg/week for rheumatoid arthritis), ibuprofen and other NSAIDs carry major severity rating rather than absolute contraindication. FDA labeling advises caution and enhanced monitoring. The mechanism is competitive inhibition of methotrexate accumulation at cellular targets, combined with reduced renal secretion. Recommended approach: avoid NSAIDs if possible; if essential, use the lowest effective dose for the shortest duration and monitor serum creatinine and complete blood count (CBC) at 2–4 week intervals. Document indication and consider gastroprotection with a proton-pump inhibitor (PPI) or H2-receptor antagonist.

Proton-Pump Inhibitors: Omeprazole and Omeprazole Magnesium

FDA labeling identifies omeprazole and omeprazole magnesium as major interactions with methotrexate. These agents decrease methotrexate clearance by unknown mechanisms (possibly reduced renal secretion or hepatic metabolism), elevating and prolonging serum MTX and hydroxymethotrexate concentrations. Risk escalates with high-dose MTX (>100 mg/m²). Clinical management: if PPI therapy is required for gastrointestinal indications, use the minimum effective dose and interval; consider H2-receptor antagonists (famotidine, ranitidine historical data) as alternatives. Monitor CBC and comprehensive metabolic panel (CMP) at baseline and 4–8 week intervals. In patients receiving concurrent MTX and PPI, reduce MTX dose by 20–30% and counsel on toxicity warning signs (mucositis, cytopenias, hepatic transaminitis).

Monitoring Strategy for MTX-Treated Patients

Comprehensive monitoring mitigates interaction risk:

• Baseline assessment: CBC, CMP including creatinine, hepatic function panel (AST, ALT, albumin), and hepatitis B/C serology
• Ongoing interval: CBC and CMP every 4–8 weeks during low-dose MTX; weekly during high-dose inpatient regimens
• Medication reconciliation: At each visit, verify absence of contraindicated drugs; assess NSAID, PPI, and trimethoprim exposure
• Renal function monitoring: Estimated glomerular filtration rate (eGFR) should be ≥60 mL/min/1.73m² for safe MTX dosing; dose adjustment required if eGFR 30–59 mL/min/1.73m²; MTX contraindicated if eGFR <30 mL/min/1.73m²
• Folate supplementation: Folic acid 1 mg daily or folinic acid (leucovorin) on non-MTX days reduces hematologic and gastrointestinal toxicity and is standard practice, independent of interactions
• Patient education: Warn against over-the-counter NSAIDs, herbal supplements (particularly those with folate antagonism), and alcohol excess (hepatotoxicity risk)

Dose Adjustment Considerations

When major interactions cannot be avoided, dose reduction is prudent:

• Low-dose MTX (≤30 mg/week): Reduce by 25–50% if concurrent major interactant is unavoidable; increase monitoring frequency to 2–4 weeks
• High-dose MTX (>100 mg/m²): Strongly favor avoidance of major interactants; if unavoidable, consult oncology and consider leucovorin rescue intensification
• Renal impairment: eGFR 30–59 mL/min/1.73m²: reduce MTX dose by 50%; eGFR <30 mL/min/1.73m²: contraindicated

Key Takeaways for Clinicians

Methotrexate's mechanism as a folate antagonist and its dependence on renal elimination create vulnerability to multiple drug-drug interactions. FDA labeling provides clear guidance: contraindicated agents (NSAIDs with high-dose MTX, TMP-SMX, nitrous oxide, natalizumab, acitretin, sepiapterin) must be absolutely avoided. Major interactants (NSAIDs with low-dose MTX, omeprazole) require dose adjustment, enhanced monitoring, and documented clinical justification. Routine laboratory surveillance (CBC, CMP, renal function) at 4–8 week intervals is essential. Patient education regarding over-the-counter medication avoidance is critical to prevent inadvertent toxicity. When prescribing or monitoring methotrexate, always reconcile the complete medication list and cross-reference against FDA-sourced interaction data.

Ensure Comprehensive Safety: Check Your Full Medication List

Methotrexate interactions extend beyond this guide. To verify that your patient's complete medication regimen is safe, use checkdruginteractions.com—the most comprehensive drug interaction checker on the internet. Our database contains over 250,000 FDA-labeled drug records, updated monthly, allowing you to screen up to 20 drugs simultaneously with instant autocomplete and severity-ranked interaction alerts. No account is required. Protect your patients by confirming drug safety today.